GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015
-
Under the terms of the license agreement between the two companies,
"Pfizer's commitment to initiating the rivipansel Phase 3 clinical trial
represents a key step in the development of this potentially important
new medication for treatment of pain crisis associated with sickle cell
disease," said
Rivipansel has received both Orphan Drug and Fast Track status for the
treatment of VOC from the FDA, and Orphan Product status in the
About
GlycoMimetics is a clinical stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of rivipansel, including expected milestone
payments from
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media